Lite Strategy, Inc.

Lite Strategy, Inc. is a pharmaceutical company that has historically developed novel and differentiated cancer therapies and, during fiscal year 2026, commenced pre-clinical development programs in nononcologic disease indications, while also holding Litecoin (LTC) tokens as a primary reserve asset as part of a broader institutional treasury initiative. The company's drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kδ inhibitor, with ME-344 sold in October 2024 to Aardvark Therapeutics, Inc. The company operates in a highly competitive pharmaceutical marketplace, competing with pharmaceutical and biotechnology companies, as well as universities and public and private research institutions, many of which have significantly greater capital resources, larger research and development staffs and facilities, and greater experience in drug development, regulation, manufacturing, marketing and commercialization. The company also operates within the digital asset space, holding LTC tokens, which are subject to a developing regulatory landscape, including the SEC's Digital Asset Interpretation issued on March 17, 2026, which classified LTC as a digital commodity, though this interpretation is not binding and could be revised or withdrawn.

The marketplace for the company's drug candidates is highly competitive, with competitors including pharmaceutical companies, biotechnology companies, universities, and public and private research institutions, many of which have significantly greater capital resources, larger research and development staffs and facilities, and greater experience in drug development, regulation, manufacturing, marketing and commercialization. The company's competitive position is supported by its intellectual property, including worldwide rights to voruciclib, with one U.S. patent covering a crystal form projected to expire in 2042, and worldwide rights to zandelisib, with nine issued U.S. patents covering composition of matter, pharmaceutical compositions, methods of use to treat cancer and combinations with additional therapies, with composition of matter claims projected to expire between 2030 and 2032. The company also holds LTC tokens as a primary reserve asset, and the SEC's Digital Asset Interpretation identified LTC as a digital commodity, though this is not binding and could change.

The company generates revenue through its pharmaceutical development activities, historically developing novel and differentiated cancer therapies, and currently assessing pre-clinical development programs in nononcologic disease indications, with potential for out-licensing or sale related opportunities. The company also holds LTC tokens as a primary reserve asset as part of its Litecoin Treasury Strategy, which involves acquiring LTC tokens and entering into contracts with GSR Markets Ltd to write covered call options on certain LTC holdings, designed to generate incremental liquidity and income while retaining exposure to the underlying digital assets. The company's primary customer segments are not explicitly detailed, but its business model involves creating value in drug programs through clinical development, strategic partnerships, and out-licensing or commercialization, as appropriate, and its digital asset strategy is part of a broader institutional treasury initiative.

Voruciclib is an oral CDK9 inhibitor that was studied in a Phase 1 trial as a single agent in patients with acute myeloid leukemia (AML) and B-cell malignancies and in combination with the BCL-2 inhibitor venetoclax in patients with AML, with all clinical trial activities ceased in September 2024. The company is currently evaluating voruciclib in a pre-clinical development program for nononcologic diseases, with preliminary ex vivo study results showing modulation of immune cell subsets, supporting further development in animal models. Zandelisib is an oral, once-daily, selective PI3Kδ inhibitor that was being developed for the treatment of indolent B-cell lymphomas, with development discontinued in November 2022 after an FDA meeting, and the company is currently assessing potential out-licensing or sale related opportunities. ME-344, an intravenous small molecule mitochondrial inhibitor, was sold in October 2024 to Aardvark Therapeutics, Inc. for development in obesity and metabolic diseases, with potential for future milestone payments of up to $62.0 million ¹ upon reaching prespecified development and commercialization targets.

The company's drug candidate pipeline includes voruciclib, an oral CDK9 inhibitor, and zandelisib, an oral selective PI3Kδ inhibitor, with ME-344 sold in October 2024 to Aardvark Therapeutics, Inc. for development in obesity and metabolic diseases, with potential for future milestone payments of up to $62.0 million ². The company also holds LTC tokens as a primary reserve asset as part of its Litecoin Treasury Strategy, which commenced on August 5, 2025, through the acquisition of LTC tokens reflecting the full deployment of the net proceeds of the PIPE. The company enters into contracts with GSR Markets Ltd to write covered call options on certain LTC holdings, designed to generate incremental liquidity and income while retaining exposure to the underlying digital assets, subject to the risk that the assets may be delivered to option counterparties if exercised.

On July 22, 2025, the company closed on a $100.0 million ³ PIPE, issuing 23,216,898 ⁴ shares of common stock at an offering price of $3.42 ⁵ per share and pre-funded warrants to purchase up to 6,022,869 ⁶ shares of common stock at an offering price of $3.4199 ⁷ per pre-funded warrant. In connection with the PIPE, the company issued Advisory Warrants for the purchase of up to 3,070,177 ⁸ shares of common stock with a weighted-average exercise price of approximately $4.10 ⁹ per share. On October 29, 2025, the Board authorized a Share Repurchase Program to repurchase shares of common stock up to an aggregate amount of $25.0 million ¹⁰, and as of June 30, 2026, the company had repurchased 4,378,525 ¹¹ shares at a weighted-average price of $1.12 ¹² per share, with approximately $20.2 million ¹³ remaining usage available. The company also sold ME-344 to Aardvark Therapeutics, Inc. in October 2024, with potential for future milestone payments of up to $62.0 million ¹⁴.

During the fiscal year ended June 30, 2026, the company incurred a net loss of $71.2 million ¹⁵, compared to a net loss of $15.9 million ¹⁶ during the fiscal year ended June 30, 2025. As of June 30, 2026, the company had an accumulated deficit of $475.3 million ¹⁷. The company's financial results are exposed to fluctuations in the market price of LTC, which has historically been volatile, and the company expects to continue to incur operating and net losses as it develops and seeks development and/or commercial relationships for its drug candidates. The company's R&D expenses have decreased in connection with the termination of all prior clinical programs, and the company expects its current unrestricted cash and cash equivalents and unrestricted digital assets to be sufficient to fund its currently anticipated operating plan for at least the next 12 months.

The company expects to continue to incur operating and net losses as it develops and seeks development and/or commercial relationships with other partners for its drug candidates, and because it holds LTC as a primary reserve asset, fluctuations in the market price of LTC, including declines below acquisition costs, may materially affect its financial condition and results of operations. The company expects its current unrestricted cash and cash equivalents and unrestricted digital assets to be sufficient to fund its currently anticipated operating plan for at least the next 12 months, though it may need to raise additional capital to continue development of its pre-clinical drug development programs or its Litecoin Treasury Strategy. The company is committed to long-term innovation in capital structure and financial technology, along with the initiation of an expanding strategy that could include the commencement of LTC mining or other crypto-focused operational activities.

The company is evaluating voruciclib in a pre-clinical development program for nononcologic diseases, with preliminary ex vivo study results showing modulation of immune cell subsets, which support further development in animal models. The company is also assessing potential out-licensing or sale related opportunities for zandelisib, and has commenced further investigational research and development pre-clinical activities with its drug candidate pipeline in nononcologic disease indications for potential out-licensing or sale related opportunities. The company's Litecoin Treasury Strategy involves acquiring LTC tokens as a primary reserve asset, and the company may commence LTC mining or other crypto-focused operational activities as part of an expanding strategy.

The company's growth vectors include the expansion of its Litecoin Treasury Strategy, which could include the commencement of LTC mining or other crypto-focused operational activities, and the initiation of pre-clinical development programs in nononcologic disease indications for its drug candidates, with potential for out-licensing or sale related opportunities. The company also holds LTC tokens as a primary reserve asset, and the SEC's Digital Asset Interpretation identified LTC as a digital commodity, which could support the company's strategy, though the interpretation is not binding and could change. The company's drug candidate pipeline includes voruciclib and zandelisib, and the company is assessing potential out-licensing or sale related opportunities for these assets.

The company expects to continue to incur operating and net losses, and its R&D expenses have decreased in connection with the termination of all prior clinical programs. The company's cost structure is expected to evolve as it continues pre-clinical development of drug candidates, maintains and expands its global intellectual property portfolio, utilizes consultants or third-party organizations or hires additional clinical, quality control and scientific personnel, and adds operational, financial and management information systems. The company's financial results may fluctuate significantly from year to year, depending on changes in the market value of its LTC holdings, the timing of the development of its drug candidates, the timing of any clinical trials, the receipt of payments under any future agreements, and expenditures on other R&D activities.

The company does not have the facilities or capabilities to commercially manufacture any of its drug candidates and expects to continue to be dependent on contract manufacturers for supplying its pre-clinical development program in nononcologic disease indications and any other future candidates. As of June 30, 2026, the company had five employees, all residing in the United States, engaged in business development, finance, information systems or administrative support, and other personnel resources are used from time to time as consultants or third-party service organizations on an as-needed basis for treasury management and scientific and human resources activities. The company's Chief Executive Officer and Chief Financial Officer has prior experience with pharmaceutical, biotechnology and medical product companies.

The company's capital allocation priorities include the Share Repurchase Program, authorized on October 29, 2025, to repurchase shares of common stock up to an aggregate amount of $25.0 million ¹⁸, with approximately $20.2 million ¹⁹ remaining usage available as of June 30, 2026. The company intends to finance the purchases using proceeds from its Covered Call Options or from the liquidation of a portion of its LTC tokens. The company has not paid any cash dividends on its common stock, other than a capital return paid on December 6, 2023, and does not anticipate paying any cash dividends in the foreseeable future, intending to retain any future earnings to finance the development and expansion of its business.

The company faces structural headwinds related to the volatility of Litecoin, which has traded between $39.39 ²⁰ and $135.56 ²¹ per Litecoin in the 12 months ended June 30, 2026, and between $39.39 ²² and $60.53 ²³ per Litecoin during the second quarter of calendar year 2026. The company's Litecoin holdings are less liquid than its existing cash and cash equivalents and may not be able to serve as a source of liquidity to the same extent, and the company may be unable to sell its Litecoin at favorable prices or at all during times of market instability. The company is also subject to regulatory developments related to crypto assets, including the possibility that Litecoin could be determined to be a security, which could adversely affect the market price of Litecoin and the company's common stock.

The company faces execution risks related to its Litecoin Treasury Strategy, including the risk of security breaches or cyberattacks that could result in the loss of some or all of its Litecoin, as well as the risk that its private keys could be lost or destroyed. The company expects that substantially all of the Litecoin it acquires will be held in custody accounts at U.S.-based institutional-grade digital asset custodians, and a successful security breach or cyberattack could result in a partial or total loss of its Litecoin in a manner that may not be covered by insurance or the liability provisions of the custody agreements. The company also faces risks related to the regulatory landscape for digital assets, including the possibility that Litecoin could be determined to be a security, which could lead to the company being deemed an unregistered investment company under the Investment Company Act of 1940, which could necessitate its liquidation or delisting from the exchange on which its stock is traded.

The price of Litecoin has been and will likely continue to be highly volatile, having traded between $39.39 ²⁴ and $135.56 ²⁵ per Litecoin in the 12 months ended June 30, 2026, and between $39.39 ²⁶ and $60.53 ²⁷ per Litecoin during the second quarter of calendar year 2026, and the company's Litecoin holdings are less liquid than its cash and cash equivalents, which could impair its ability to meet working capital requirements if it is forced to sell at a loss. The company is exposed to the risk that Litecoin could be determined to be a security under federal or state securities laws, which could lead to the company being deemed an unregistered investment company under the Investment Company Act of 1940, potentially necessitating liquidation or delisting, and could adversely affect the market price of Litecoin and the company's common stock. The company faces significant cybersecurity and operational risks related to its Litecoin holdings, as a security breach or cyberattack could result in the partial or total loss of its Litecoin, and access to its LTC accounts requires private keys, with three separate keys for approval, and if any single approval key was lost, destroyed or otherwise compromised, the company may be unable to access its LTC holdings until such key was replaced. The company has incurred significant losses from inception, with a net loss of $71.2 million ²⁸ for fiscal year 2026 and an accumulated deficit of $475.3 million ²⁹ as of June 30, 2026, and expects to continue to incur losses for the foreseeable future, which may require additional funding that could be unavailable on acceptable terms. The company's common stock is listed on the Nasdaq Capital Market, and failure to maintain a minimum closing bid price of $1.00 ³⁰ per share could result in delisting, which would negatively impact liquidity, the ability to raise equity financing, and the company's reputation.

Management's message emphasizes the company's transformation from a pharmaceutical company focused on developing novel and differentiated cancer therapies to one that also holds Litecoin tokens as a primary reserve asset as part of a broader institutional treasury initiative, with the commencement of the Litecoin Treasury Strategy on August 5, 2025, reflecting the full deployment of the net proceeds of the PIPE. The company is committed to long-term innovation in capital structure and financial technology, along with the initiation of an expanding strategy that could include the commencement of LTC mining or other crypto-focused operational activities, and has commenced further investigational research and development pre-clinical activities with its drug candidate pipeline in nononcologic disease indications for potential out-licensing or sale related opportunities. Management's strategic priorities include the implementation and execution of the Litecoin Treasury Strategy, the pre-clinical development of drug candidates in nononcologic disease indications, and the assessment of potential out-licensing or sale related opportunities for zandelisib, while managing the risks inherent in operating a cryptocurrency business and safekeeping cryptocurrency assets.